Speaker: Dr. Peng Wang, President of R&D of Yabao Pharmaceutical Group Corp. and CEO and CSO of Suzhou Yabao Pharmaceutical R&D Company, China
The environment for new drug development in China is improving rapidly, including funding, talent pool, standards and quality, government regulation, etc. This results in China becoming a better place for drug development although drug discovery remains a relatively weak area in China. Yabao Pharmaceutical Group (www.yabao.cn/en), a leading Chinese pharmaceutical company, has created a new business model for drug co-development collaboration in China on early-stage drug candidates from western companies or institutions. In 2014 the company signed four collaboration deals on new drug candidates with from University of South Australia, Lilly, Lawson Institute of Canada and MRC Technology of UK. The company is still actively seeking more opportunities for such collaboration as well as the manufacturing and commercial collaboration.
In this seminar, Dr. Wang, Corporate Vice President and President of R&D at Yabao Pharmaceutical, will introduce the status of new drug R&D in China, the improving environment and the Yabao’s model for co-development collaboration. He will also present details of the types of new drug candidates and other collaboration opportunities the company is seeking.
Venue: Karolinska Institutet Science Park Conference, Tomtebodavägen 23a in Solna